Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:clinicalTrials |
Phase II
Phase III Phase I differentiated thyroid carcinoma advanced hepatocellular carcinoma advanced renal cell carcinoma |
| gptkbp:contraindication |
anemia
nausea vomiting liver toxicity pregnancy breastfeeding cardiovascular events hypothyroidism thrombocytopenia neutropenia severe liver impairment hand-foot syndrome |
| gptkbp:developedBy |
gptkb:Bayer
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:future_plans |
clinical trials
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sorafenib
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
warfarin CYP3A4 inducers |
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:marketedAs |
Nexavar
|
| gptkbp:patentExpiration |
2020
|
| gptkbp:researchAreas |
drug development
oncology pharmacology |
| gptkbp:sideEffect |
fatigue
hypertension diarrhea rash |
| gptkbp:skills |
400 mg
200 mg |
| gptkbp:storage |
room temperature
protected from moisture |
| gptkbp:targets |
gptkb:VEGFR
PDGFR RAF_kinase |
| gptkbp:triggerType |
inhibitor of multiple kinases
|
| gptkbp:type |
Sorafenib_tosylate
|
| gptkbp:usedFor |
treatment of thyroid cancer
treatment of kidney cancer treatment of liver cancer |
| gptkbp:year |
2005
|